TAK-438 Enters into Phase III Clinical Trials in Japan for the Treatment of Acid-related Diseases
Advertisement
Takeda Pharmaceutical Company Limited announced that TAK-438 has entered into Phase III clinical trials in Japan for the treatment of patients with acid-related diseases such as reflux esophagitis.
TAK-438, originated by Takeda, is a potassium-competitive acid blocker (P-CAB) that suppresses gastric acid secretion by inhibiting the binding of potassium ion (K+) to H+, K+-ATPase (proton pump). It has a different mechanism of action from proton pump inhibitors (“PPIs”).
TAK-438 is anticipated to have, in clinical use, a more potent inhibitory effect on gastric acid secretion, a faster onset of action, and a longer lasting effect than PPIs. The Phase III clinical trials in Japan are multi-centric, and designed to evaluate the safety and efficacy of TAK-438 for diseases such as gastric ulcer, duodenal ulcer and reflux esophagitis.
“There are still many patients with acid-related diseases who have severe conditions, or not responsive to PPI therapy,” said Nancy Joseph-Ridge, M.D., Corporate Officer and General Manager, Pharmaceutical Development Division of Takeda. “Leveraging our extensive experience in the area of gastroenterology, we will efficiently conduct the development activities of TAK-438 so that we can offer another potential new treatment option to these patients as quickly as possible.”
Most read news
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Why is junk food more attractive when on diet? - New insights into why we crave fatty foods when dieting
KWS and BASF collaborate to develop high-yielding sugar beet - New varieties expected on the global market from 2020

New and presumably tick-borne bacterium discovered
Field trials with genetically enhanced potatoes - Field trials in Germany, Sweden and the Netherlands
Kras gene linked to pancreatic cancer growth, U-M study finds - Inactivating Kras caused tumors to disappear, suggesting possible treatment target
